Nanobody-based CAR T cells targeting intracellular tumor antigens
Chimeric antigen receptor (CAR) T-cell immunotherapy has become one of the research hotspots in the treatment of malignant tumors nowadays. However, the available tumor surface antigens are limited in number. Most tumor-associated antigens are intracellular molecules that can’t be targeted by conven...
Main Authors: | Haixia Li, Dani Zhong, Huiguan Luo, Wei Shi, Shenxia Xie, Hangbiao Qiang, Lichen Zhu, Li Gao, Jun Liu, Shuyang Sun, Ziqiang Ding, Xiaomei Yang, Xiaoling Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-12-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332222013087 |
Similar Items
-
Nanobody Based Dual Specific CARs
by: Stijn De Munter, et al.
Published: (2018-01-01) -
A general approach for stabilizing nanobodies for intracellular expression
by: John G Dingus, et al.
Published: (2022-11-01) -
The Application of Nanobody in CAR-T Therapy
by: Chaolemeng Bao, et al.
Published: (2021-02-01) -
Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology
by: Keming Lin, et al.
Published: (2024-04-01) -
Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells
by: Hongxia Wang, et al.
Published: (2021-08-01)